Invivyd, Inc. (IVVD)

USD 0.44

(-9.27%)

Market Cap (In USD)

53.18 Million

Revenue (In USD)

-

Net Income (In USD)

-198.64 Million

Avg. Volume

646.56 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.4414-5.195
PE
-
EPS
-
Beta Value
0.656
ISIN
US00534A1025
CUSIP
00534A102
CIK
1832038
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Robert D. Allen Ph.D.
Employee Count
-
Website
https://adagiotx.com
Ipo Date
2021-08-06
Details
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.